UOC
GLMD icon

UBS O'Connor’s Galmed Pharmaceuticals GLMD Stock Holding History

UBS O'Connor’s Portfolio GLMD Stock Details GLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-591
Closed -$726K – 70
2018
Q4 		$726K Sell
591
-62
-9% -$108K 0.03% 179
2018
Q3 		$1.6M Sell
653
-41
-6% -$96K 0.04% 184
2018
Q2 		$1.49M Buy
+694
New +$1M 0.03% 178

Other funds holding GLMD

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
II
Ibex Investors Denver, Colorado $152M AUM 19.17% 1-Year Est. Return
MIH
Meitav Investment House Bene-Beraq, Israel $9.12B AUM 42.07% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
FMBTD
First Midwest Bank Trust Division Joliet, Illinois $777M AUM 29.48% 1-Year Est. Return
PAWC
P.A.W. Capital Greenwich, Connecticut $88.2M AUM 25.13% 1-Year Est. Return

UBS O'Connor's GLMD Position: Q1 2019 in Review

UBS O'Connor sold out of Galmed Pharmaceuticals (GLMD) in Q1 2019, closing a stake of 591 shares — an estimated $726K sold.

UBS O'Connor first reported a position in GLMD in Q2 2018 and held it in 3 quarters. The position peaked at $1.6M in Q3 2018. 34 funds tracked by Wall St. Rank hold GLMD as of Q1 2019.

  • UBS O'Connor reported no remaining Galmed Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
  • UBS O'Connor sold 591 Galmed Pharmaceuticals shares in Q1 2019, an estimated $726K.
  • UBS O'Connor first reported a position in Galmed Pharmaceuticals in Q2 2018 and held it in 3 quarters.
  • UBS O'Connor's Galmed Pharmaceuticals position peaked at $1.6M in Q3 2018.
  • 34 funds tracked by Wall St. Rank held Galmed Pharmaceuticals as of Q1 2019.

Based on UBS O'Connor's 13F filing for Q1 2019, filed 13 May 2019.